J Korean Neuropsychiatr Assoc.  2002 May;41(3):421-429.

Depression in Schizophrenia

Affiliations
  • 1Department of Psychiatry, College of Medicine, The Chung-Ang University Hospital, Seoul, Korea.

Abstract


OBJECTIVE
The heterogeneity of symptomatology within the group of schizophrenias is still a major obstacle for defining clinically useful subgroups of these disorders. One of these symptoms is depression. Recently there is a growing evidence suggesting that depressive symptoms and related mood disturbances are important in treating schizophrenia. This is so because of the improvement of such side effects as extrapyramidal symptoms with increasing use of atypical antipsychotics. Although depression is known to be a serious problem of many schizophrenic patients, the nature and course of depression in schizophrenia remain unknown.
METHODS
The author examined the depressive features in 31 patients with schizophrenia. Ratings on the PANSS, BDI and HDRS were obtained. Eighteen percent of the total patients had BDI score above 21, considered depressed.
RESULTS
There were no differences in BDI, HDRS and PANSS-D between positive symptom group and negative symptom group. There was also no correlation between subject scale(BDI) and objective scales(HDRS, PANSS-D).
CONCLUSIONS
Depression in schizophrenia needs intensive studies. It is also considered as another heterogeneous domain beside negative or positive symptom domains. Out of respect for the high prevalence and serious outcome of depression in schizophrenia, a more differentiated assessment, analysis, and treatment of depressive symptom is recommended.

Keyword

Schizophrenia; Depression; BDI; HDRS; PANSS

MeSH Terms

Antipsychotic Agents
Depression*
Humans
Population Characteristics
Prevalence
Schizophrenia*
Antipsychotic Agents
Full Text Links
  • JKNA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr